Introduction {#sec1}
============

*Streptococcus pneumoniae* is a leading respiratory pathogen that is responsible for infections such as pneumonia, meningitis, bacteremia and otitis media. In 2003, the World Health Organization (WHO) estimated that pneumococcal disease is responsible for 1 million deaths annually, most of which occur in children \<5 years of age in the developing world [@bib1]. Although pneumococcal meningitis is relatively rare, it is strongly associated with mortality or subsequent neurologic damage [@bib2].

Pneumococcal resistance to penicillin was first described in 1967, and since the 1990s an increasing rate of resistance has been reported worldwide [@bib3; @bib4]. This resistance makes the treatment of serious pneumococcal infections difficult, and many antibiotic treatment failures have been reported [@bib5].

In Algeria, several reports have shown an increase in antibiotic resistance from 1996 to 2010, especially among children [@bib6; @bib7; @bib8; @bib9]. Although epidemiologic surveillance data for invasive pneumococcal infections are available, clinical data are lacking. Moreover, since the introduction of *Haemophilus influenzae* type b vaccination in 2008 in Algeria, *S. pneumoniae* has become the predominant pathogen in bacterial meningitis (unpublished data).

The *S. pneumoniae* polysaccharide capsule is a major virulence factor; more than 90 serotypes have been identified, and their distribution differs in different regions and between developing and developed countries [@bib10]. This highlights the importance of having national data before implementation of a pneumococcal vaccine. The aim of the study was to investigate the evolution of antibiotic resistance and serotype distribution of *S. pneumoniae* in infections in children in Algeria.

Material and methods {#sec2}
====================

From January 2005 to June 2012, a total of 270 unique *S. pneumoniae* isolates were collected from children aged 0 to 16 years with invasive and noninvasive infections; about 89% were from Algiers and 11% from Oran, a town located in the western part of the country. The hospital clinical laboratories were asked to send all their viable isolates. Every year, the centers isolate between 15 and 50 *S. pneumoniae* strains from children who are diagnosed by physicians with invasive pneumococcal disease (IPD) and non-IPD (NIPD). *S. pneumoniae* isolates were identified by colony morphology, Gram staining, catalase reaction, optochin susceptibility and bile lysis. Antibiotic susceptibilities for oxacillin, erythromycin, clindamycin, tetracyclin, chloramphenicol and cotrimoxazole were determined following the Clinical and Laboratory Standards Institute (CLSI) recommendations [@bib11; @bib12]. Minimum inhibitory concentrations (MICs) for penicillin, amoxicillin and cefotaxim were determined using the E-test following the manufacturer\'s instructions (Solna, Sweden) for all strains. The *S. pneumoniae* ATCC 49619 strain was used for quality control.

Serotyping was performed by latex agglutination for determining pools, and serotypes were identified using the Neufeld test (Pneumo test latex; Statens Serum Institute, Copenhagen, Denmark). A total of 127 isolates were serotyped, 85 from invasive samples and 42 from noninvasive samples. The isolates that were serotyped were selected on the basis of the clinical data, with priority given to IPD and the number of viable isolates. Isolates were stored in 10% glycerol broth at −80°C after primary isolation.

Results {#sec3}
=======

From the 270 isolates collected (IPD *n* = 97, NIPD *n* = 173), 197 (73.0%) were from children \<5 years, of whom 151 (76.7%) were \<2 years. Among the isolates from children with IPD, 78.4% were collected from children \<5 years of age, of whom 76.3% were \<2 years old. The IPD isolates were collected from children with meningitis (*n* = 53), pneumonia and pleuropneumonia (*n* = 25), bacteremia (*n* = 11), arthritis or peritonitis infections (*n* = 8). The non-IPD isolates were from ear, nose and throat infections (*n* = 91), bronchopulmonary infections (*n* = 77) and other suppurative infections (*n* = 5). Among the isolates from children with NIPD, 69.9% were from children \<5 years of age; 53.8% were \<2 years old ([Table 1](#tbl1){ref-type="table"}).

Nonsusceptibility to penicillin was detected in 48% of the *S. pneumoniae* isolates (MICs ranged from 0.016 μg/mL to 4 μg/mL); 2.6% of isolates had intermediate resistance to amoxicillin; 7% and 1.7% of isolates had intermediate and full resistance to cefotaxime, respectively. For the IPD isolates, the MIC90s were 2 μg/mL for penicillin and amoxicillin and 1.5 μg/mL for cefotaxime. The highest rate of cefotaxim resistance was observed in isolates from meningitis: 20.8% intermediate and 3.8% resistant ([Table 2](#tbl2){ref-type="table"}).

The percentages of isolates that were resistant to non-β-lactam antibiotics were 53.0% for erythromycin and cotrimoxazole; 43.7% for clindamycin; 42.0% for tetracycline; and 5.3% for chloramphenicol. According to the new breakpoints suggested by CLSI, whereby meningitis and nonmeningitis isolates have different breakpoints, 49.0% of the meningitis isolates were resistant to penicillin (MIC ≥0.12 μg/mL), among which 26.9% had a MIC of ≥2 μg/mL.

After meningitis isolates, the next highest rate of penicillin-nonsusceptible *S. pneumoniae* (PNSP) was observed in the isolates from NIPD. From all the invasive isolates (*n* = 97), 40.3% were PNSP, with 81.5% of these from children \<5 years and 72.7% from children \<2 years.

Among the 85 IPD samples that were serotyped, meningitis was the most common diagnosis, at 50 (58.8%), followed by pneumonia and pleuropneumonia, at 21 (24.7%), and bacteremia, at 9 (10.6%) ([Table 3](#tbl3){ref-type="table"}). The prevalence of IPD in children aged \<5 years and \<2 years was 78.3% (*n* = 76) and 59.8% (*n* = 58), respectively ([Table 1](#tbl1){ref-type="table"}). The most frequent serotypes for invasive isolates were 14 (29.4%), 1 (10.6%), 19F (10.6%), 19A (7%), 6B (7%), 5 (4.7%), 3 (4.7%), 6A (3.5%) and 23F (3.5%). Serotype 14 was the most prevalent in meningitis (34%) and pleuropneumonia (28.6%), while serotypes 19F (38%) and 14 (23.8%) were the most frequent in noninvasive samples ([Table 3, Fig. I](#tbl3 fig1){ref-type="table"}). In order of prevalence, serotypes 14, 19F, 6B, 19A, 1, 5, 23F, 6A, 3, 7F and 18C accounted for 91.0% of IPD in children \<5 years old. Serotypes 5, 7F, 6B, 18C and 19A were found exclusively in children \<2 years of age.

The serotypes that were most often antibiotic resistant were 14, 19F, 19A and 6B; they were mainly highly resistant to penicillin, and only serotypes 14 and 19A were resistance to cefotaxime ([Fig. 2](#fig2){ref-type="fig"}, [Table 4](#tbl4){ref-type="table"}).

Discussion {#sec4}
==========

The prevalence of penicillin resistance among pneumococcal disease isolates in Algeria, which was measured by the oxacillin disc diffusion method, appears to have increased over the years, from 34.6% in 1995--2000 to 48.1% in 2005--2012 (current study) [@bib6; @bib7; @bib8; @bib9]. The percentage of PNSP among IPD isolates in children was reported to be approximately 11% in Western European countries, with the highest percentage (49%) in Spain [@bib1].

Our results are more consistent with the increasing antibiotic resistance rates reported for North African countries. For instance, in Tunisia and Morocco, the rates of PNSP were, respectively, 52.8% and 43.3% [@bib6; @bib7; @bib8; @bib9; @bib13; @bib14; @bib15]. The dramatic increase in the antibiotic resistance rate since our previous study (PNSP of 48.1% in this study compared with 34.6% in 2001) could be explained by overuse of antibiotics for acute respiratory tract infections in Algeria [@bib8].

We also observed an evolution in the serotype distribution in Algeria. Although the distribution is similar to that reported for Morocco and Tunisia, as well as other developing countries, it differs from that reported in our previous study, where we found that serotypes/serogroups 1, 5, 14 and 6 were the most frequent [@bib8; @bib9; @bib15; @bib16].

Some pneumococcal serotypes, such as serotypes 1, 5 and 7F, have more invasive potential than others; serotype 7F has been reported to be associated with a higher risk of severe and fatal outcomes [@bib17]. In Africa, serotypes 1 and 5 are commonly associated with invasive diseases. In Algeria, the frequency of serotype 1 was low during the 2002--2004 and 2005--2007 periods but increased in 2008--2009 (unpublished data). Similar observations of cyclical peaks in serotype 1 incidence have been reported in many countries. Although serotypes 1 and 5 are designated as 'developing country serotypes,' they have also been reported to be frequently responsible for pediatric IPD in industrialized countries such as Germany, Sweden and England [@bib18; @bib19]. Serotype 1 has remained one of the most prevalent invasive serotypes and is usually associated with meningitis outbreaks in Africa and in crowded communities [@bib16; @bib20]. It is ranked as one of the four serotypes with the highest IPD burden in Africa, Asia and Latin American, while serotype 5 is ranked third in Africa and Latin America and fourth in Asia [@bib10]. In Thailand, the seven most frequent serotypes associated with IPD in patients \<5 years old were 6B, 23F, 14, 19F, 19A, 6A, and 4 or 9V [@bib21].

Two studies in Oxford and Stockholm that characterized the genotypes and serotypes of nasopharyngeal and invasive pneumococcal isolates from children and adults identified serotypes 1, 4 and 7F as having a high level of invasiveness, and serotypes 3 and 7F as having a higher case fatality rate compared with other serotypes [@bib22].

The predominant serotypes of PNSP in our study are similar to those reported in other studies and previous studies in Algeria, with the emergence of serotype 19A in the absence of routine pneumococcal vaccination in our country [@bib2; @bib8; @bib9; @bib14; @bib15]. The most commonly multidrug-resistant serotypes among the PNSP were 19A, 19F, 14 and 6B, which were resistant to erythromycin, cotrimoxazole, clindamycin and tetracycline.

Serotype 14 is one of the most invasive serotypes that can cause life-threatening IPDs. Moreover, it can harbour multiple resistance determinants, conferring resistance to penicillin, erythromycin and cefotaxime [@bib23]. In many countries the multidrug-resistant serotype 19A has become the most predominant nonvaccine serotype isolated after PCV7 vaccination [@bib24].

On the basis of the serotype distribution observed in our study, the PCV7 coverage in children \<5 years of age with IPD in Algeria is 55.3%, the PCV10 coverage is 71.1% and the PCV13 coverage is 86.8%. This vaccine coverage among children \<2 years is 51.7% for PCV7, 69% for PCV10 and 87.9% for PCV13. These data may not reflect the situation in all cases of IPD in the studied regions because many children with IPD are treated empirically. In addition, the limitations of existing diagnostic tests affect the ability to obtain accurate IPD burden data: only 10% of blood culture results are positive, so most patients with pneumonia are not bacteriemic [@bib25]. In Algeria, the lack of laboratory facilities, including no facilities for storing samples frozen at −80°C in different regions of the country, is another limiting factor for conducting a multicenter study in order to obtain accurate IPD burden data. Despite limited financial resources dedicated to IPD surveillance in Algeria, we have conducted a nasopharyngeal carriage in healthy children and the most prevalent serogroups were 6, 14 and 19 (23rd European Congress of Clinical Microbiology and Infectious Diseases, abstract R2717).

The pneumococcal conjugate vaccines (PCVs) currently available have been shown to protect children. The first licensed 7-valent vaccine, which was widely used, resulted in dramatic reductions in pneumococcal disease mortality and morbidity. The emergence of the multidrug-resistant serotype 19A and the absence of the so-called developing country serotypes, 1 and 5, has led manufacturers to develop higher valency PCVs, such as PCV9, PCV10, PCV11 and PCV13 [@bib26]. The WHO recommends the inclusion of PCVs in childhood immunization programs worldwide, especially in countries with childhood mortality that exceeds 50 deaths per 1000 births [@bib27]. Although there are some limitations with our study, the results show that the burden of IPD is high in our country. The good vaccine serotype coverage suggests that the introduction of childhood vaccination with PCVs could be expected to have a dramatic effect on the burden of IPD in our country.

Continuous national monitoring of IPD and nasopharyngeal carriage as well as judicious use of antibiotics are crucial before and after PCV implementation in order to evaluate the effect of vaccination and to prevent the selection of multidrug-resistant clones.
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###### 

Number of *Streptococcus pneumoniae* isolates by sample origin and patient age

  Sample                                               Patient age   Total        
  ---------------------------------------------------- ------------- ------- ---- -----
  Invasive samples                                                                
   CSF                                                 30            10      13   53
   Blood culture[1](#tbl1fn1){ref-type="table-fn"}     15            4       2    21
   Puncture fluids[2](#tbl1fn2){ref-type="table-fn"}   13            4       6    23
   Total                                               58            18      21   97
  Noninvasive samples                                                             
   Lower respiratory tract samples                     57            8       12   77
   Auricular swabs                                     31            7       9    47
   Sinus and nasal aspirates                           5             10      29   44
   Other samples[3](#tbl1fn3){ref-type="table-fn"}     0             3       2    5
   Total                                               93            28      52   173
  Overall total                                        151           46      73   270

Pneumonia (*n* = 10), bacteremia (*n* = 11).

Pleural (*n* = 15), joint (*n* = 5), peritoneal (*n* = 3).

Conjunctive (*n* = 4), genital sample (*n* = 1).

###### 

MICs for penicillin, amoxicillin and cefotaxime in isolates from IPD and NIPD

  Disease                  Penicillin   Amoxicillin   Cefotaxime                                                   
  ------------------------ ------------ ------------- ------------ ----- ----- ------ ----- --- ------ ----- ----- -----
  Meningitis (*n* = 53)                 49            0.3          2           20.8             1.5          3.8   0.4
  Other IPD (*n* = 44)     20.4         27.2          0.5          2     6.8   2.3    0.5   2   4.5    0     0.5   1.5
  Total IPD (*n* = 97)     10           39.2          0.38         2     3.1   1      0.5   2   13.4   2     0.5   1.5
  Otitis (*n* = 47)        25.5         10.6          0.8          2     0     0      1     2   0      0     0.5   1
  LRTI (*n* = 77)          34.6         32.7          1            2     4.1   0      1.5   4   0      2     0.5   2
  Other NIPD (*n* = 49)    34.2         2.5           0.2          1.5   2.5   0      0.3   2   2.5    0     0.2   1.5
  Total NIPD (*n* = 173)   31.4         16            0.5          2     2.2   0      0.8   4   0.8    0.8   0.5   1.5

Global MICs were as follows: penicillin, I = 20.6%, R = 27.5%; amoxicillin, I = 2.56%, R = 0.42%; cefotaxime, I = 7%, R = 1.68%.

MIC, minimum inhibitory concentration; IPD, invasive pneumococcal disease; I, intermediate resistance; R, resistant; LRTI, lower respiratory tract infection; NIPD, noninvasive pneumococcal disease.

###### 

Serotype distribution among isolates from children with IPD and NIPD

  Serotype   Age \<5 years   Age 5--16 years   Overall total                                                     
  ---------- --------------- ----------------- --------------- --- ---- ---- --- ----- ---- --- --- --- --- ---- -----
  14         2               15                6                   23   5    3   31    2            1   1   4    35
  19F        2               3                 2                   7    10   6   23    2                    2    25
  6B         1               3                 2                   6    2        8                          0    8
  23F        1               0                 1                   2    2        4     1                    1    5
  18C                                                          1   1    1        2                          0    2
  4                                                                              0     1                    1    1
  1          1               4                                 1   6             6     1    2               3    9
  5                          2                 2                   4             4                          0    4
  7F                         1                 1                   2             2                          0    2
  3                          2                                     2    1        3     2            1       3    6
  6A         1               1                                     2             2              1           1    3
  19A                        2                 2               2   6    4        10                         0    10
  35B                        1                                     1             1                  2       2    3
  9A                         1                                     1             1                  1       1    2
  16F                                                                            0     1    1               2    2
  23B                                                                   1        1     1                    1    2
  6C                         1                                     1             1                          0    1
  8                                                                              0          1               1    1
  12                                           1                   1             1                          0    1
  17F                                                                            0     1                    1    1
  23A                                                                            0     1                    1    1
  24A                                                                            0                      1   1    1
  28F                        1                                     1             1                          0    1
  35F        1                                                     1             1                          0    1
  Total      9               37                17              4   67   26   9   102   13   4   1   5   2   25   127

IPD, invasive pneumococcal disease; NIPD, noninvasive pneumococcal disease.

###### 

Resistance profiles by isolated *S. pneumoniae* serotypes

  Antimicrobial                   14       19F      6B      23F     5       7F      6A      19A     16F     24A     28F     Total
  ------------------------------- -------- -------- ------- ------- ------- ------- ------- ------- ------- ------- ------- --------
  oxa                             2        2                                                                                **4**
  oxa, sxt                        10                                                                                1       **11**
  oxa, sxt, tet                   1                                                                                         **1**
  oxa, ery, clin                  4                                                                                         **4**
  oxa, ery, clin, sxt             4        6        1                               1       1                               **13**
  oxa, ery, clin, tet             1        7                2       1                                                       **11**
  oxa, ery, sxt, tet              1                                                         1       1                       **3**
  oxa, ery, clin, sxt, tet        5        5        3                       1               6               1               **21**
  oxa, ery, clin, chl, sxt, tet                     1                                                                       **1**
  Total                           **28**   **20**   **5**   **2**   **1**   **1**   **1**   **8**   **1**   **1**   **1**   **69**

oxa = oxacillin; sxt = cotrimoxazole; tet = tetracyclin; ery = erythromycin; clin = clindamycin; chl = chloramphenicol.
